Truist raised the firm’s price target on Labcorp (LH) to $310 from $290 and keeps a Buy rating on the shares. Truist remains bullish on Labcorp following Q2 results that featured beats on the top and bottom lines, solid trends across segments with operating margin expansion and raised FY guidance, the analyst tells investors in a research note. Financial flexibility remains attractive, supporting execution on the pipeline and return of value to shareholders, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp price target raised to $302 from $290 at Baird
- Labcorp price target raised to $306 from $283 at Morgan Stanley
- Positive Outlook for Labcorp Holdings: Buy Rating Justified by Strong Future Prospects and Strategic Growth Initiatives
- Labcorp Reports Strong Q2 2025 Results, Raises Guidance
- Labcorp Holdings Reports Strong Growth and Raises Guidance